A public-private partnership encompassing pharmaceutical companies, patient charities and the U.K. government have committed funding to establish a $100 million venture capital fund designed to invest in early-stage dementia research. It is hoped such an approach to funding Alzheimer’s research might come up trumps where other methods have failed.
The Dementia Discovery Fund, described as the first VC fund to target a specific disease, is being backed by
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?